TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02732860

Intervention type: OTHER
Intervention: Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures
Description: Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.

Intervention type: OTHER
Intervention: Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures
Description: Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.

Intervention type: OTHER
Intervention: Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures
Description: Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.
Study: NCT01942889

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant Supplementation associated to Comprehensive respiratory Rehabilitation Program
Description: Vit E, Vit C, Selenomethionine, Zinc gluconate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Antioxidant Supplementation associated to Comprehensive respiratory Rehabilitation Program
Description: Vit E, Vit C, Selenomethionine, Zinc gluconate
Study: NCT00018356

Intervention type: PROCEDURE
Group type: OTHER
Intervention: exercise

Intervention type: DRUG
Group type: OTHER
Intervention: testosterone
Study: NCT00632827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Colony-stimulating factor 3 (CSF 3) and, is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. May be used instead of G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cancer medication that interferes with the growth and spread of cancer cells in the body

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine is a chemotherapy medication used to treat cancer. Vincristine works by stopping the cancer cells from separating into 2 new cells to stops the growth of the cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin is used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate is a chemotherapy medication used to treat cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Doxorubicin Hydrochloride is a chemotherapy medication used to treat cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide is a is a chemotherapy medication used to treat cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Carmustine is a chemotherapy medication used to treat cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox
Description: Denileukin diftitox is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells
Study: NCT00625196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone foroate/ vilanterol
Description: Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone foroate
Description: Fluticasone foroate 800 micrograms will be available as dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone foroate
Description: Fluticasone foroate 800 micrograms will be available as dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol
Description: Vilanterol will be available as dry powder inhaler.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vilanterol
Description: Vilanterol will be available as dry powder inhaler.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as dry powder inhaler.
Study: NCT02516098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyoscine butylbromide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyoscine butylbromide
Study: NCT04342494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Feedback + Standard Feedback
Description: Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Headspace app + Standard Feedback
Description: Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Headspace is an app designed to train the user in mindfulness practices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Headspace app + Enhanced Feedback + Standard Feedback
Description: Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Headspace is an app designed to train the user in mindfulness practices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SilverCloud + Standard Feedback
Description: Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Silvercloud is an app designed to deliver cognitive behavioral therapy.
Study: NCT02686138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Study: NCT01463553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS pleurodesis
Description: Based on the findings, establish selection standards for the timing of surgery to treat PSP by VATS and establish technical specifications for performing operations on different types of lung bullae. The goal is to improve the diagnosis and treatment of PSP so as to reduce the recurrence rate of pneumothorax, reduce the trauma of operation, shorten hospital stays and postoperative recovery time, and provide better services for returning to everyday life and improving the quality of life for patients.
Study: NCT04608526

Intervention type: DIAGNOSTIC_TEST
Intervention: Fractal analysis
Description: Fractal dimension (FD) analysis, which can be measured in panoramic radiographs, is a technique that can be used to measure mandibular trabecular architecture and to determine early periodontal changes in alveolar bone. Fractal analysis method, which has become more and more popular in recent years; has features such as being easily accessible, not being affected by variables such as projection geometry and radiological density and providing objective data about trabecular structures. It can be measured in the patients' existing panoramic images and does not require extra imaging and material.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fractal analysis
Description: Fractal dimension (FD) analysis, which can be measured in panoramic radiographs, is a technique that can be used to measure mandibular trabecular architecture and to determine early periodontal changes in alveolar bone. Fractal analysis method, which has become more and more popular in recent years; has features such as being easily accessible, not being affected by variables such as projection geometry and radiological density and providing objective data about trabecular structures. It can be measured in the patients' existing panoramic images and does not require extra imaging and material.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fractal analysis
Description: Fractal dimension (FD) analysis, which can be measured in panoramic radiographs, is a technique that can be used to measure mandibular trabecular architecture and to determine early periodontal changes in alveolar bone. Fractal analysis method, which has become more and more popular in recent years; has features such as being easily accessible, not being affected by variables such as projection geometry and radiological density and providing objective data about trabecular structures. It can be measured in the patients' existing panoramic images and does not require extra imaging and material.
Study: NCT03352830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RANAS Behavior Change Intervention
Description: The Risks, Attitudes, Norms, Abilities, and Self-Regulation (RANAS) Model is a health behavior change intervention, which has been successfully used in the area of water, sanitation, and hygiene. It draws from numerous health behavior theories, including the Theory of Planned Behavior, the Health Action Process, and the Health Belief Model. The model posits that the five factor blocks (risks, attitudes, norms, abilities, and self-regulation) that must be aligned toward the new behavior in order to influence change. A series of activities target each block accordingly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RANAS Behavior Change Intervention
Description: The Risks, Attitudes, Norms, Abilities, and Self-Regulation (RANAS) Model is a health behavior change intervention, which has been successfully used in the area of water, sanitation, and hygiene. It draws from numerous health behavior theories, including the Theory of Planned Behavior, the Health Action Process, and the Health Belief Model. The model posits that the five factor blocks (risks, attitudes, norms, abilities, and self-regulation) that must be aligned toward the new behavior in order to influence change. A series of activities target each block accordingly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infrastructural Intervention - Direct Delivery
Description: Product demand is influenced, in part, by accessibility. Investigators are testing the degree to which this is true for liquefied petroleum gas (LPG) by establishing a direct delivery system for communities randomized to this treatment arm. Individuals in these communities are able to contact a 'delivery agent', contracted by the Kintampo Health Research Centre, who will: 1) retrieve their cylinder, 2) refill with LPG, and 3) return to the participant. The cost of delivery is free to the participant (paid by the study), but the participant is expected to fully pay for their own LPG.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infrastructural Intervention - Direct Delivery
Description: Product demand is influenced, in part, by accessibility. Investigators are testing the degree to which this is true for liquefied petroleum gas (LPG) by establishing a direct delivery system for communities randomized to this treatment arm. Individuals in these communities are able to contact a 'delivery agent', contracted by the Kintampo Health Research Centre, who will: 1) retrieve their cylinder, 2) refill with LPG, and 3) return to the participant. The cost of delivery is free to the participant (paid by the study), but the participant is expected to fully pay for their own LPG.
Study: NCT02006745

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: 24 weeks in those achieving RVR (undetectable HCV RNA at 4 weeks) or 48 weeks in those not achieving RVR

Intervention type: DRUG
Group type: OTHER
Intervention: Telaprevir
Description: 12 weeks in those achieving RVR, 24 weeks in those not achieving RVR (HCV RNA \>25 but \<1000 iU/mL at week 4) or 48 weeks in those not achieving RVR (HCV RNA \>1000 iU/mL at week 4).
Study: NCT00434330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 milligram per kilogram (mg/kg) for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered intravenously (IV) once every 4 weeks for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
Study: NCT02732860

Intervention type: OTHER
Intervention: Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures
Description: Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.
Study: NCT04342494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SilverCloud app +Enhanced Feedback +Standard Feedback
Description: Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Silvercloud is an app designed to deliver cognitive behavioral therapy.
Study: NCT02522585

Intervention type: OTHER
Intervention: Conservative management
Description: Control of CIN-II with cytology and colposcopy to try to avoid unnecessary surgery
Study: NCT02464995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty with the Alair System
Study: NCT00434330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
Study: NCT04666584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ScoreFlex balloon
Description: Pre-dilatation with a ScoreFlex balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: standard non-compliant balloon
Description: Pre-dilatation with a standard non-compliant balloon
Study: NCT02697812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: slow sternal retraction
Description: the sternal retraction (which always need to be performed for coronary artery bypass graft surgery) will be achieved over 15 min instead of the usual 30 sec
Study: NCT00875251

Intervention type: DEVICE
Intervention: body composition
Description: Measurements of body composition using 2 differents devices: Bioimpedance measurements will be made with the RJL System (Quantum BIA 101Q equipment) air-displacement plethysmography in the PEA POD System (Life Measurement).
Study: NCT02686138

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01962207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm
Study: NCT02632474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)
Description: The first 2 weeks, TDF (300 mg) + 3-TC (300 mg) + EFV (400 mg); week 3, TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg ); week 4, TDF (150 mg) + 3-TC (300 mg) + EFV (400 mg).From week5, if the HIV viral load decreased as expected or no rebound, use TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg) until study complete; if the viral load increases, switch to the standard treatment regimen: TDF (300 mg) + 3-TC (300 mg) + EFV (600 mg).
Study: NCT04432857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN0025
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN0025
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN0025
Description: oral administration
Study: NCT02733380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30mg , Oral twice a week(with an interval of no less than 3 days,;e.g. Monday and Thursday，Tuesday and Friday) until disease progression or unacceptable toxicity develops
Study: NCT04432857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN0025
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN0025
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN0025
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Infusion
Study: NCT01082406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) administered iv.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant factor XIII
Description: Single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) to be administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv.
Study: NCT02733380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 20mg/m2， IV on day 1 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin or mitoxantrone
Description: 20mg/m2, IV on day 1 of each 14 day cycle（Note：for patients who can not afford the liposomal doxorubicin，may be replaced into mitoxantrone 8mg/m2, IV on day1 of each 14 day cycle） until disease progression or unacceptable toxicity develops, up to 12 cycles